Karyopharm Therapeutics (KPTI) Convertible Debt (2018 - 2024)

Karyopharm Therapeutics has reported Convertible Debt for 7 years, with the latest figure at $171.1 million in Q1 2024.

• For the quarter ending Q1 2024, Convertible Debt changed 0.48% year-over-year to $171.1 million; the trailing twelve-month figure through Mar 2024 stood at $171.1 million (changed 0.48% YoY), and the FY2023 full-year result was $170.9 million, changed 0.48% from the prior year.
• Convertible Debt for Q1 2024 stood at $171.1 million, roughly flat from $170.9 million in the prior quarter.
• The five-year high for Convertible Debt was $171.1 million in Q1 2024, with the low at $111.8 million in Q1 2020.
• Historically, Convertible Debt has averaged $156.9 million across 5 years, with a median of $169.5 million in 2022.
• Annual changes were most pronounced in 2021 — Convertible Debt surged 50.94% — and 2022, when it gained 0.47%.
• Karyopharm Therapeutics' Convertible Debt stood at $117.9 million in 2020, then jumped by 43.56% to $169.3 million in 2021, then climbed by 0.48% to $170.1 million in 2022, then advanced by 0.48% to $170.9 million in 2023, then gained by 0.12% to $171.1 million in 2024.
• The last three Convertible Debt figures came in at $171.1 million (Q1 2024), $170.9 million (Q4 2023), and $170.7 million (Q3 2023), per Business Quant data.